Transposagen Biopharmaceuticals, Inc. has entered into a research and worldwide license agreement with Janssen Biotech to develop allogeneic Chimeric Antigen Receptor T-cells (CAR-T). CAR-T therapies have shown promise in early trials for the treatment of blood cancers and have the potential for use as off-the-shelf cancer treatments without the need of matching donor with recipient.   Transposagen will use its genome editing technologies, including the piggyBac Footprint-Free Gene Editing Syste...